Enhancement of the antigen‑specific cytotoxic T lymphocyte‑inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector‑mediated transduction of the caTLR4 gene

Iwabuchi,Minami; Narita,Miwako; Uchiyama,Takayoshi; Iwaya,Shunpei; Oiwa,Eri; Nishizawa,Yoshinori; Hashimoto,Shigeo; Bonehill,Aude; Kasahara,Noriyuki; Takizawa,Jun; Takahashi,Masuhiro

doi:10.3892/mmr.2015.3685

Enhancement of the antigen‑specific cytotoxic T lymphocyte‑inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector‑mediated transduction of the caTLR4 gene

Authors:
- Minami Iwabuchi
- Miwako Narita
- Takayoshi Uchiyama
- Shunpei Iwaya
- Eri Oiwa
- Yoshinori Nishizawa
- Shigeo Hashimoto
- Aude Bonehill
- Noriyuki Kasahara
- Jun Takizawa
- Masuhiro Takahashi
View Affiliations

Affiliations: Laboratory of Hematology and Oncology, Graduate School of Health Sciences, Niigata University, Nagaoka, Niigata 951‑8518, Japan, Division of Hematology, Nagaoka Red Cross Hospital, Nagaoka, Niigata 951‑8518, Japan, Laboratory of Cellular and Molecular Therapy, Department of Physiology and Immunology, Medical School of the Free University Brussels (VUB), Laarbeeklaan 103, 1090 Brussels, Belgium, CURE Vector Core & JCCC Vector Shared Resource Facility, University of California, Los Angeles, CA 90095, USA, Division of Hematology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Niigata University, Niigata 951‑8510, Japan
Published online on: April 24, 2015 https://doi.org/10.3892/mmr.2015.3685
Pages: 2443-2450
Copyright: © Iwabuchi et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to enhance the efficiency of leukemia immunotherapy by increasing the antigen‑specific cytotoxic T lymphocyte‑inducing ability of leukemia cells. The leukemic plasmacytoid dendritic cell line PMDC05 containing the HLA‑A02/24 antigen, which was previously established in our laboratory (Laboratory of Hematology and Oncology, Graduate School of Health Sciences, Niigata University, Niigata, Japan), was used in the present study. It exhibited higher expression levels of CD80 following transduction with lentiviruses encoding the CD80 gene. This CD80‑expressing PMDC05 was named PMDC11. In order to establish a more potent antigen‑presenting cell for cellular immunotherapy of tumors or severe infections, PMDC11 cells were transduced with a constitutively active (ca) toll‑like receptor 4 (TLR4) gene using the Tet‑On system (caTLR4‑PMDC11). CD8+ T cells from healthy donors with HLA‑A02 were co‑cultured with mutant WT1 peptide‑pulsed PMDC11, lipopolysaccharide (LPS)‑stimulated PMDC11 or caTLR4‑PMDC11 cells. Interleukin (IL)‑2 (50 IU/ml) and IL‑7 (10 ng/ml) were added on day three of culture. Priming with mutant WT1 peptide‑pulsed PMDC11, LPS‑stimulated PMDC11 or caTLR4‑PMDC11 cells was conducted once per week and two thirds of the IL‑2/IL‑7 containing medium was replenished every 3‑4 days. Immediately prior to the priming with these various PMDC11 cells, the cultured cells were analyzed for the secretion of interferon (IFN)‑γ in addition to the percentage and number of CD8+/WT1 tetramer+ T cells using flow cytometry. caTLR4‑PMDC11 cells were observed to possess greater antigen‑presenting abilities compared with those of PMDC11 or LPS‑stimulated PMDC11 cells in a mixed leukocyte culture. CD8 T cells positive for the WT1 tetramer were generated following 3‑4 weeks of culture and CD8+/WT1 tetramer+ T cells were markedly increased in caTLR4‑PMDC11‑primed CD8+ T cell culture compared with PMDC11 or LPS‑stimulated PMDC11‑primed CD8+ T cell culture. These CD8+ T cells co‑cultured with caTLR4‑PMDC11 cells were demonstrated to secrete IFN‑γ and to be cytotoxic to WT1‑expressing target cells. These data suggested that the antigen‑specific cytotoxic T lymphocyte (CTL)‑inducing ability of PMDC11 was potentiated via transduction of the caTLR4 gene. The present study also suggested that caTLR4‑PMDC11 cells may be applied as potent antigen‑presenting cells for generating antigen‑specific CTLs in adoptive cellular immunotherapy against tumors and severe viral infections.

View Figures

View References

1	Steinman RM and Banchereau J: Taking dendritic cells into medicine. Nature. 449:419–426. 2007. View Article : Google Scholar : PubMed/NCBI
2	Sims RB: Development of sipuleucel-T: Autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer. Vaccine. 30:4394–4397. 2012. View Article : Google Scholar
3	Montagna D, Turin I, Schiavo R, et al: Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor. Cytotherapy. 14:80–90. 2012. View Article : Google Scholar
4	Narita M, Watanabe N, Yamahira A, et al: A leukemic plasmacytoid dendritic cell line, PMDC05, with the ability to secrete IFN-alpha by stimulation via Toll-like receptors and present antigens to naive T cells. Leuk Res. 33:1224–1232. 2009. View Article : Google Scholar : PubMed/NCBI
5	Watanabe N, Narita M, Yamahira A, et al: Transformation of dendritic cells from plasmacytoid to myeloid in a leukemic plasmacytoid dendritic cell line (PMDC05). Leuk Res. 34:1517–1524. 2010. View Article : Google Scholar : PubMed/NCBI
6	Yamahira A, Narita M, Nakamura T, et al: Generation of antigen-specific cytotoxic T lymphocytes using a leukemic plasmacytoid dendritic cell line as antigen presenting cells. Leuk Res. 35:793–799. 2011. View Article : Google Scholar : PubMed/NCBI
7	Yamahira A, Narita M, Ishii K, et al: Enhancement of antigen presenting ability in the leukemic plasmacytoid dendritic cell line (PMDC05) by lentiviral vector-mediated transduction of CD80 gene. Leuk Res. 36:1541–1546. 2012. View Article : Google Scholar : PubMed/NCBI
8	Stripecke R: Lentiviral vector-mediated genetic programming of mouse and human dendritic cells. Methods Mol Biol (Clifton, NJ). 506:139–158. 2009.
9	Pincha M, Salguero G, Wedekind D, et al: Lentiviral vectors for induction of self-differentiation and conditional ablation of dendritic cells. Gene Ther. 18:750–764. 2011. View Article : Google Scholar : PubMed/NCBI
10	Takahashi M, Shigeno N, Takahashi H, et al: Effects of transfection of p210bcr-abl and bcr-v-abl into the factor-dependent human leukemia cell line HSM-911. Leuk Res. 21:1115–1123. 1997. View Article : Google Scholar
11	Narita M, Masuko M, Kurasaki T, Kitajima T, Takenouchi S, Saitoh A, Watanabe N, Furukawa T, Toba K, Fuse I, Aizawa Y, Kawakami M, Oka Y, Sugiyama H and Takahashi M: WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in chronic phase. Int J Med Sci. 7:72–81. 2010. View Article : Google Scholar : PubMed/NCBI
12	Yamanaka R, Homma J, Yajima N, et al: Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: Results of a clinical phase I/II trial. Clin Cancer Res. 11:4160–4167. 2005. View Article : Google Scholar : PubMed/NCBI
13	Irvine DJ and Doh J: Synthetic surfaces as artificial antigen presenting cells in the study of T cell receptor triggering and immunological synapse formation. Semin Immunol. 19:245–254. 2007. View Article : Google Scholar : PubMed/NCBI
14	Koffeman E, Keogh E, Klein M, Prakken B and Albani S: Identification and manipulation of antigen specific T-cells with artificial antigen presenting cells. Methods Mol Med. 136:69–86. 2007.PubMed/NCBI
15	Rudolf D, Silberzahn T, Walter S, et al: Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells. Cancer Immunol Immunother. 57:175–183. 2008. View Article : Google Scholar
16	Steenblock ER, Wrzesinski SH, Flavell RA and Fahmy TM: Antigen presentation on artificial acellular substrates: modular systems for flexible, adaptable immunotherapy. Expert Opin Biol Ther. 9:451–464. 2009. View Article : Google Scholar : PubMed/NCBI
17	Cai Z, Brunmark A, Jackson MR, Loh D, Peterson PA and Sprent J: Transfected Drosophila cells as a probe for defining the minimal requirements for stimulating unprimed CD8⁺ T cells. Proc Natl Acad Sci USA. 93:14736–14741. 1996. View Article : Google Scholar
18	Hasan AN, Kollen WJ, Trivedi D, et al: A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy. J Immunol. 183:2837–2850. 2009. View Article : Google Scholar : PubMed/NCBI
19	Papanicolaou GA, Latouche JB, Tan C, et al: Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele. Blood. 102:2498–2505. 2003. View Article : Google Scholar : PubMed/NCBI
20	Yuan J, Gallardo HF, Rasalan T, et al: In vitro expansion of Ag-specific T cells by HLA-A*0201-transfected K562 cells for immune monitoring. Cytotherapy. 8:498–508. 2006. View Article : Google Scholar
21	Butler MO, Lee JS, Ansén S, et al: Long-lived antitumor CD8⁺ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res. 13:1857–1867. 2007. View Article : Google Scholar : PubMed/NCBI
22	Sasawatari S, Tadaki T, Isogai M, Takahara M, Nieda M and Kakimi K: Efficient priming and expansion of antigen-specific CD8⁺ T cells by a novel cell-based artificial APC. Immunol Cell Biol. 84:512–521. 2006. View Article : Google Scholar : PubMed/NCBI
23	Chaperot L, Blum A, Manches O, et al: Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J Immunol (Baltimore, Md. 150). 176. pp. 248–255. 2006
24	Di Domizio J, Blum A, Gallagher-Gambarelli M, Molens JP, Chaperot L and Plumas J: TLR7 stimulation in human plasmacytoid dendritic cells leads to the induction of early IFN-inducible genes in the absence of type I IFN. Blood. 114:1794–1802. 2009. View Article : Google Scholar : PubMed/NCBI
25	Maeda T, Murata K, Fukushima T, et al: A novel plasmacytoid dendritic cell line, CAL-1, established from a patient with blastic natural killer cell lymphoma. Int J Hematol. 81:148–154. 2005. View Article : Google Scholar : PubMed/NCBI
26	Sapienza MR, Fuligni F, Agostinelli C, et al: Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-κB pathway inhibition. Leukemia: official journal of the Leukemia Society of America; Leukemia Research Fund, U.K.: 2014
27	Aspord C, Charles J, Leccia MT, et al: A novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells. PLoS ONE. 5:e104582010. View Article : Google Scholar
28	Stone AE, Giugliano S, Schnell G, et al: Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cells. PLoS Pathogens. 9:e10033162013. View Article : Google Scholar : PubMed/NCBI
29	Narita M, Kuroha T, Watanabe N, et al: Plasmacytoid dendritic cell leukemia with potent antigen-presenting ability. Acta Haematol. 120:91–99. 2008. View Article : Google Scholar : PubMed/NCBI
30	Cisco RM, Abdel-Wahab Z, Dannull J, et al: Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4. J Immunol (Baltimore, Md. 1950). 172:7162–7168. 2004. View Article : Google Scholar
31	Abdel-Wahab Z, Cisco R, Dannull J, et al: Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses. J Surg Res. 124:264–273. 2005. View Article : Google Scholar : PubMed/NCBI
32	Bonehill A, Tuyaerts S, Van Nuffel AM, et al: Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther. 16:1170–1180. 2008. View Article : Google Scholar : PubMed/NCBI